| Company Name: |
ALS INDIA LIFE SCIENCES
|
| Tel: |
+91-8977036379 |
| Email: |
alsindialife@gmail.com |
| Products Intro: |
Product Name:N-(3-Ethynyl-4-methylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine
CAS:1346601-52-2
Purity:95.00% Package:1 kg,5 kg, 10 kg,25kg and 1 MT
|
|
| | 4-Methyl Erlotinib Hydrochloride Basic information |
| | 4-Methyl Erlotinib Hydrochloride Chemical Properties |
| Melting point | 224-228°C (dec.) | | Boiling point | 567.5±50.0 °C(Predicted) | | density | 1.23±0.1 g/cm3(Predicted) | | storage temp. | -20°C Freezer | | solubility | Chloroform (Slightly), DMSO, Methanol (Slightly) | | pka | 5.33±0.30(Predicted) | | form | Solid | | color | Pale Pink to Pale Brown |
| | 4-Methyl Erlotinib Hydrochloride Usage And Synthesis |
| Uses | Erlotinib (E625000) derivative as internal standard for HPLC. | | Biological Activity | 4-methyl erlotinib is an analog of erlotinib by the addition of a methyl group at the four position of the phenyl group. erlotinib is a tyrosine kinase inhibitor which acts on the epidermal growth factor receptor (egfr) [1].the epidermal growth factor receptor (egfr) autocrine pathway has been important for cancer development and progression, including cell proliferation, apoptosis, angiogenesis, and metastatic spread [2].erlotinib inhibits egfr-associated kinase activity by binding to the egf-activated receptor, with the phenyl group at one end sequestered in a hydrophobic pocket of the kinase domain and the ether linkages at the opposite end projecting into solvent [1].erlotinib can prolong survival in patients with non–small-cell lung cancer after first-line or second-line chemotherapy [3]. | | references | [1] stamos, j. ,sliwkowski, m.x. and eigenbrot, c. structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. the journal of biological chemisty 277(48), 46265-46272 (2002).
[2] ciardiello f, tortora g. a novel approach in the treatment of cancer: targeting the epidermal growth factor receptor[j]. clinical cancer research, 2001, 7(10): 2958-2970.
[3] shepherd f a, rodrigues pereira j, ciuleanu t, et al. erlotinib in previously treated non–small-cell lung cancer[j]. new england journal of medicine, 2005, 353(2): 123-132. |
| | 4-Methyl Erlotinib Hydrochloride Preparation Products And Raw materials |
|